Skip to content
Screener

Kura Oncology KURA Darlifarnib — Research And Development Expense

Similar metrics at other companies

Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%
Innoviva, Inc. logo
INVAInternal Expenses — Research And Development Expense
$2.73M+127%
Disc Medicine logo
IRONOther Research — Research And Development Expense
$2.17M+18.2%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M—
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$849.57M+76.7%
Enterprise value$834.76M+99.5%
P/S11.9×+3.3×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219481
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Less:
Cost of product sales262—
Ziftomenib-related costs36,88029,947
Darlifarnib-related costs6,5675,235
Discovery stage program-related costs1,4002,089
Research and development personnel costs and other expenses17,20115,374
Share-based compensation expense8,4167,842
Other segment expenses(1)26,35418,321

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Kura Oncology's darlifarnib — research and development expense?
Kura Oncology (KURA) reported darlifarnib — research and development expense of $6.57M in Q1 2026.
How has Kura Oncology's darlifarnib — research and development expense changed year-over-year?
Kura Oncology's darlifarnib — research and development expense increased by 25.4% year-over-year, from $5.24M to $6.57M.
What does darlifarnib — research and development expense mean?
This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the Darlifarnib product candidate. It captures the investment intensity required to progress this specific asset through clinical trials and toward potential commercialization. Monitoring this expense helps investors assess the company's capital allocation strategy and the pace of development for this key pipeline asset.

Ask your AI about Kura Oncology's darlifarnib — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude